Published in Bioterrorism Week, February 16th, 2009
ABthrax is a first-in-class treatment for anthrax, and the first procurement under Project BioShield of a product discovered and developed after the September 11, 2001 terrorist attacks. It specifically targets the deadly toxins released within the human body by Bacillus anthracis that are the real culprits in most anthrax-related deaths. ABthrax is being developed under a contract entered into in 2006 with the Biomedical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Bioterrorism Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.